Mr. R.M. Rumble reports

TSO3 ENTERS INTO FIRST COMMERCIAL AGREEMENT FOR STERIZONE

TSO3 Inc. has signed its first commercial agreement with Getinge Infection Control in support of the launch of the Sterizone VP4 sterilization system. The non-exclusive agreement covers multiple markets in which Getinge has significant market share, including North America and other selected markets. Efforts to launch the product will begin immediately.

"We are extremely pleased to have Getinge Infection Control representing our Sterizone technology," stated R.M. (Ric) Rumble, president and chief executive officer. "Our recent efforts which resulted in bolstering our balance sheet means that TSO3 has the financial resources available to support Getinge's sales efforts and after, sales service support. Getinge has watched the progression of our technology through the U.S. regulatory process and with U.S. clearance now in hand, both organizations see the opportunity to launch this superior technology in North America and selected additional markets," concluded Mr. Rumble.

"Getinge Infection Control is the world leader in sterile reprocessing of reusable medical devices," stated Andrew Ray, president and CEO of Getinge Infection Control North America. "The TSO3 technology fills a gap in our portfolio and is a natural fit for our commercial team. Our entire organization is anxious to get started assisting our mutual customers understand how this technology improves their process and reduces the cost of sterilization while improving patient outcomes," concluded Mr. Ray.

We seek Safe Harbor.